Toggle Health Problems and D

COVID-19 ICU survival rate increased 7X by daily Omega-3 – RCT March 2021

The effect of omega-3 fatty acid supplementation on clinical and biochemical parameters of critically ill patients with COVID-19: a randomized clinical trial

Journal of Translational Medicine vol 19, # 128 (2021)
Saeid Doaei, Somayeh Gholami, Samira Rastgoo, Maryam Gholamalizadeh, Fatemeh Bourbour, Seyedeh Elaheh Bagheri, Forough Samipoor, Mohammad Esmail Akbari, Mahdi Shadnoush, Fereshteh Ghorat, Seyed Alireza Mosavi Jarrahi, Narjes Ashouri Mirsadeghi, Azadeh Hajipour, Parvin Joola, Alireza Moslem & Mark O. Goodarzi
Statistically significant differences


1) Omega-3 was given for 14 days or death in ICU
2) Omega-3 can be given at >2X daily rate for many weeks
3) Emulsified Omega-3 is 3X more bio-available than standard Omega-3 (low-fat meal)
      it appears that standard Omega-3 was given in this RCT
4) Omega-3 reduces all-cause mortality in non-COVID-19 settings as well
5) Weekly Omega-3 might be better than daily- similar to Vitamin D


Vitamin D and Omega-3 category starts with

394 Omega-3 items in category Omega-3 helps with: Autism (8 studies), Depression (29 studies), Cardiovascular (34 studies), Cognition (49 studies), Pregnancy (40 studies), Infant (32 studies), Obesity (13 studies), Mortality (7 studies), Breast Cancer (5 studies), Smoking, Sleep, Stroke, Longevity, Trauma (12 studies), Inflammation (18 studies), Multiple Sclerosis (9 studies), VIRUS (12 studies), etc
CIlck here for details

Omega-3 and Virus items

Omega-3 and Mortality items

Omega-3 is very important to health

Importance to Health VDW10426

Omega-3 index is very low in many places around the world - 2016

Omega 3 Index Map VDW 7552
Omega-3 map (most of the world has low levels) – May 2016
Note: This RCT was done in Iran
Omega-3 RDAs around the world: 100 to 2400 mg per day, US still has no RDA – Dec 2018

Web on Omega-3 and COVID-19

Other than Omega-3

COVID-19 risks reduced by Vitamin D, Magnesium, Zinc, Resveratrol, Omega-3, etc. (auto-updated)

Mortality and Virus studies (mainly Vitamin D)

COVID-19 treated by Vitamin D - studies, reports, videos

5 most-recently changed Virus entries

Magnesium and Virus items

Thanks to Dr. Grant for pointing out this RCT. He got it from Michael Mindlin

 Download the PDF from VitaminDWiki

Omega-3 polyunsaturated fatty acids (n3-PUFAs) may exert beneficial effects on the immune system of patients with viral infections. This paper aimed to examine the effect of n3-PUFA supplementation on inflammatory and biochemical markers in critically ill patients with COVID-19.

A double-blind, randomized clinical trial study was conducted on 128 critically ill patients infected with COVID-19 who were randomly assigned to the intervention (fortified formula with n3-PUFA) (n = 42) and control (n = 86) groups. Data on 1 month survival rate, blood glucose, sodium (Na), potassium (K), blood urea nitrogen (BUN), creatinine (Cr), albumin, hematocrit (HCT), calcium (Ca), phosphorus (P), mean arterial pressure (MAP), O2 saturation (O2sat), arterial pH, partial pressure of oxygen (PO2), partial pressure of carbon dioxide (PCO2), bicarbonate (HCO3), base excess (Be), white blood cells (WBCs), Glasgow Coma Scale (GCS), hemoglobin (Hb), platelet (Plt), and the partial thromboplastin time (PTT) were collected at baseline and after 14 days of the intervention.

The intervention group had significantly higher 1-month survival rate and higher levels of arterial pH, HCO3, and Be and lower levels of BUN, Cr, and K compared with the control group after intervention (all P < 0.05). There were no significant differences between blood glucose, Na, HCT, Ca, P, MAP, O2sat, PO2, PCO2, WBCs, GCS, Hb, Plt, PTT, and albumin between two groups.

Omega-3 supplementation improved the levels of several parameters of respiratory and renal function in critically ill patients with COVID-19. Further clinical studies are warranted.

Trial registry: This study was registered in the Iranian Registry of Clinical Trials (IRCT); Trial registration number: IRCT20151226025699N3; Date of registration: 2020.5.20; URL of trial registry record: https://en.irct.ir/trial/48213
Clipped from PDF
The intervention group received one capsule of 1000 mg omega-3 daily (Vita Pharmed, Switzerland) containing 400 mg EPAs and 200 mg DHAs for 14 days through adding the supplement to their enteral formula. Omega-3 fatty acids fortifed formula was administered to the case group by a nurse, who was not a member of the research team, for 2 weeks after the frst 24 h of hospitalization in ICU.

Created by admin. Last Modification: Sunday October 2, 2022 01:23:12 GMT-0000 by admin. (Version 27)

Attached files

ID Name Comment Uploaded Size Downloads
15480 Omega-3 COVID-19 GRH.jpg admin 22 Apr, 2021 60.46 Kb 480
15459 Omega-3 table.jpg admin 18 Apr, 2021 22.73 Kb 498
15458 Omega-3 COVID-19 RCT.pdf admin 18 Apr, 2021 705.67 Kb 336